Latest From Immunomedics Inc.
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.
Only two novel oncologics have cleared the FDA’s approval bar in 2019, but the Pink Sheet’s user fee tracker shows at least eight candidates under review, along with seven significant new indications and formulations.
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
- Large Molecule
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Immunomedics Inc.
- Senior Management
Usama Malik, CFO & CBO
Brendan Delaney, Chief Commercial Officer
Morris Rosenberg, CTO
- Contact Info
Phone: (973) 605-8200
300 The American Rd.
Morris Plains, NJ 07950
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.